Participate in a clinical study as a potential new anti-cancer drug, called elraglusib.
Purpose: to evaluate the safety, tolerability and how the body processes an investigational medication of an anti-cancer drug, called elraglusib.
Reimbursement for study participation will be provided for time and travel of up to $5,680
This study has been reviewed by an independent ethics committee
Call 612-315-6490 to discuss your eligibility today!